Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05132075 · ClinicalTrials.gov registry record · Phase 3
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 95
- Enrollment target
- 20
- Study locations
NCT05132075 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 95 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05132075, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 95 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination.
Conditions Studied
Interventions
- DRUG docetaxel
- DRUG JDQ443
Study Locations (20)
Other
- Novartis Investigative Site - Chongqing
- Novartis Investigative Site - Turku
- Novartis Investigative Site - Athens
Buenos Aires
- Novartis Investigative Site - CABA
- Novartis Investigative Site - Pilar
Queensland
- Novartis Investigative Site - Auchenflower
- Novartis Investigative Site - South Brisbane
Quebec
- Novartis Investigative Site - Montreal
- Novartis Investigative Site - Sherbrooke
Guangdong
- Novartis Investigative Site - Guangzhou
- Novartis Investigative Site - Guangzhou
Washington
- Valley Medical Center Research - Renton
Beijing Municipality
- Novartis Investigative Site - Beijing
Fujian
- Novartis Investigative Site - Fuzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2022-06-15 |
| Est. Completion | 2026-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05132075
The ClinicalTrials.gov registry entry for NCT05132075 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which docetaxel is the first listed.
NCT05132075 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Buenos Aires, Queensland.
Frequently Asked Questions
What is clinical trial NCT05132075 about?
NCT05132075 is a clinical study titled "Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer". This is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor t...
What is the current status of trial NCT05132075?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 95 participants. The study started on 2022-06-15. Estimated completion is 2026-03-30.
What conditions does trial NCT05132075 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05132075?
The interventions under investigation include: docetaxel (DRUG), JDQ443 (DRUG).
Who is sponsoring clinical trial NCT05132075?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05132075 being conducted?
This trial has 20 study locations across Washington, Buenos Aires, Queensland, Quebec, Beijing Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.